Minimal Trauma Fractures Research Articles

Osteoporosis treatment: a missed opportunity.

Osteoporosis affects 1.2 million Australians and, in 2012, fractures due to osteoporosis and osteopenia in Australians aged over 50 years cost $2.75 billion. Even minor minimal trauma fractures are associated with increased morbidity and mortality. Despite increasing therapeutic options for managing osteoporosis, fewer than 20% of patients with a minimal trauma fracture are treated or investigated for osteoporosis, so under-treatment is extremely common. Fracture risk assessment is important for selecting patients who require specific anti-osteoporosis therapy. Post-menopausal osteoporosis is frequently due to an imbalance in bone remodelling, with bone resorption exceeding bone formation. Antiresorptive drugs reduce the number, activity and lifespan of osteoclasts, and include bisphosphonates, oestrogen, selective oestrogen receptor-modulating drugs, strontium ranelate, and the human monoclonal antibody denosumab. Teriparatide is the only anabolic agent currently available that stimulates osteoblast recruitment and activity; its antifracture efficacy for non-vertebral fractures increases with the duration of therapy for up to 2 years when it is associated with persisting increases in bone formation rate at the tissue level. Newer anabolic agents are imminent and include an analogue of parathyroid hormone-related protein, abaloparatide, and a humanised monoclonal antibody to an inhibitor of bone formation, romosozumab. Selection of anti-osteoporosis therapy should be individualised to patients, and the duration of bisphosphonate therapy has been covered in recent guidelines. The benefits of treatment far outweigh any risks associated with long term treatment. General practitioners need to take up the challenge imposed by osteoporosis and become champions of change to close the evidence-treatment gap.

Characteristics Of Hip Fracture Patients With And Without Previous Minimal Trauma Fractures: Are We Missing Secondary Prevention?

Characteristics Of Hip Fracture Patients With And Without Previous Minimal Trauma Fractures: Are We Missing Secondary Prevention?

Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.

Postmenopausal women with breast cancer on aromatase inhibitor (AI) treatment are at increased risk of bone mineral density loss, which may lead to minimal trauma fractures. We examined the cost-effectiveness of dual energy X-ray absorptiometry (DXA) with antiresorptive (AR) therapy compared with fracture risk assessment, lifestyle advice, and vitamin supplementation. We used a hypothetical Markov cohort model of lifetime duration for 60-year-old women with early stage breast cancer receiving AIs. The data to inform the model came from medical literature, epidemiological reports, and costing data sets. Two eligibility scenarios for AR therapy were considered: (A) osteoporosis and (B) osteopenia or osteoporosis. The main outcomes were incremental cost per quality-adjusted life years gained and cumulative fractures per 1000 women, calculated relative to the comparator. Key aspects of the model were explored in sensitivity analyses. Due to relatively low effectiveness gains, the outcomes were primarily driven by the costs. The incremental cost per quality-adjusted life year gained was A$47,556 and A$253,000 for scenarios A and B, respectively. The numbers of fractures avoided were 56 and 77 per 1000 women, respectively. The results were most sensitive to the initial probability of osteoporosis, baseline risk of fracture, and cohort starting age. Compared with risk assessment and lifestyle advice only, a DXA scan followed by an AR treatment is potentially cost-effective for women aged 60 and over undergoing AI therapy for early breast cancer. However, the number of fractures averted through this intervention is small.

PILL Series. Vitamin D deficiency.

Vitamin D deficiency is common and may contribute to osteopenia, osteoporosis and falls risk in the elderly. Screening for vitamin D deficiency is important in high-risk patients, especially for patients who suffered minimal trauma fractures. Vitamin D deficiency should be treated according to the severity of the deficiency. In high-risk adults, follow-up serum 25-hydroxyvitamin D concentration should be measured 3-4 months after initiating maintenance therapy to confirm that the target level has been achieved. All patients should maintain a calcium intake of at least 1,000 mg for women aged ≤ 50 years and men ≤ 70 years, and 1,300 mg for women > 50 years and men > 70 years.

The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency

Mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autosomal recessive (AR) hyper-IgE syndrome (HIES). Recognizing patients with CID/HIES is of clinical importance because of the difference in prognosis and management. We sought to define the clinical features that distinguish DOCK8 deficiency from other forms of HIES and CIDs, study the mutational spectrum of DOCK8 deficiency, and report on the frequency of specific clinical findings. Eighty-two patients from 60 families with CID and the phenotype of AR-HIES with (64 patients) and without (18 patients) DOCK8 mutations were studied. Support vector machines were used to compare clinical data from 35 patients with DOCK8 deficiency with those from 10 patients with AR-HIES without a DOCK8 mutation and 64 patients with signal transducer and activator of transcription 3 (STAT3) mutations. DOCK8-deficient patients had median IgE levels of 5201 IU, high eosinophil levels of usually at least 800/μL (92% of patients), and low IgM levels (62%). About 20% of patients were lymphopenic, mainly because of low CD4(+) and CD8(+) T-cell counts. Fewer than half of the patients tested produced normal specific antibody responses to recall antigens. Bacterial (84%), viral (78%), and fungal (70%) infections were frequently observed. Skin abscesses (60%) and allergies (73%) were common clinical problems. In contrast to STAT3 deficiency, there were few pneumatoceles, bone fractures, and teething problems. Mortality was high (34%). Acombination of 5 clinical features was helpful in distinguishing patients with DOCK8 mutations from those with STAT3 mutations. DOCK8 deficiency is likely in patients with severe viral infections, allergies, and/or low IgM levels who have a diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchymal lung abnormalities, retained primary teeth, and minimal trauma fractures.

Integrated therapies for osteoporosis and sarcopenia: from signaling pathways to clinical trials.

Sarcopenia and osteoporosis are two sides of the same coin. They represent different aspects of the same age-related process of musculoskeletal atrophy and together culminate in falls, fractures, deconditioning, and increased mortality in older individuals. However, the current therapeutic approach to the prevention of minimal trauma fracture is unilateral and focuses solely on bone. In theory, an integrated approach that recognizes the interaction between muscle and bone could break the vicious cycle of their combined involution and more effectively minimize falls/fractures. In this review, signaling pathways and cross-talk mechanisms that integrate bone/muscle, and the emergence of novel therapies that exploit these pathways to target osteoporosis/sarcopenia will be discussed. In broad terms, these agents act on nuclear receptors (e.g., VDR, AR) or transmembrane receptors (e.g., activins, GH/IGF-1) expressed in muscle and bone, and seek to alter biologic responses to musculoskeletal aging, loading, and injury. Challenges in the development of these dual bone-muscle therapies, early clinical trials examining their safety/efficacy, and novel targets that hold promise in the reversal of musculoskeletal aging will be discussed.

Minimal-trauma fracture in women with breast cancer surviving for at least 5years from diagnosis.

Minimal-trauma fracture is an important issue in breast cancer survivors, especially rib fracture. The likelihood of fracture is affected by menopausal status and a diagnosis of osteoporosis prior to breast cancer. Most women reported at least one assessment of bone mineral density. We have investigated the self-reported frequency and pattern of minimal-trauma fracture (MTF) in breast cancer (BC) survivors at least 5 years from diagnosis, along with the use of bone mineral density (BMD) assessment. This study was carried out within the Bupa Health Foundation Health and Wellbeing After Breast Cancer Study which is a questionnaire-based prospective cohort study of 1683 women diagnosed with their first invasive breast cancer between 2004 and 2006 and followed for at least 5 years. One thousand two hundred and five women, who remained free of recurrence or new breast cancer, completed the fifth annual follow-up. One hundred sixty-four (13.6%) reported at least one MTF. Rib fracture was the most common (52 fractures in 46 women). Compared with women who remained pre-/peri-menopausal, either being postmenopausal at diagnosis (OR 3.53, 95% Confidence Interval (CI) 1.09-11.44, p=0.036) or changing from pre- to postmenopausal during follow-up (OR 3.97, 95% CI 1.21-13.10, p=0.023) was associated with a higher likelihood of fracture, as was having a diagnosis of osteoporosis at the time of diagnosis (OR 1.74, 95% CI 1.00-2.99, p=0.047). Most women (64.9%) reported at least one BMD assessment. Overall MTF is a problem for breast cancer survivors, with rib fracture a particular issue for women in our study. Both pre-existing osteoporosis and being postmenopausal are risk factors for subsequent MTF in women treated for breast cancer. Clinicians need to be mindful of fracture prevention medication in these groups.

Testosterone levels increase in association with recovery from acute fracture in men.

In this longitudinal case-control study, acute fracture was associated with low serum testosterone, which was transient in 43% of men. While assessment of gonadal status is part of the assessment of bone fragility, measurement of testosterone in the early period after fracture may overestimate the prevalence of androgen deficiency. Measurement of circulating testosterone is recommended in the evaluation of bone fragility in men. Since acute illness can transiently decrease circulating testosterone, we quantified the association of acute fracture and serum testosterone levels. A case-control study was conducted involving 240 men with a radiologically confirmed minimal trauma fracture presenting to a tertiary referral hospital and 89 age-matched men without a history of minimal trauma fracture serving as controls. Follow-up testosterone levels 6 months after baseline were available for 98 cases and 27 controls. Results were expressed as the median and interquartile (IQR) range. Compared to controls, cases had lower total testosterone [TT, 7.2 (3.5, 10.8) vs 13.6 (10.9, 17.1) nmol/L, p < 0.001]. The 143 cases treated as inpatients had lower testosterone levels than the 97 cases treated as outpatients [TT 4.7 (2.3, 8.1) vs 10.3 (7.5, 12.7) nmol/L, p < 0.001]. Group differences in calculated free testosterone (cFT) were comparable to the group differences in TT. At follow-up, in 98 cases, median TT increased from 6.5 nmol/L (3.2, 8.5) to 9.6 nmol/L (6.9, 12.0) p < 0.0001, and SHBG remained unchanged. Of cases with low testosterone, 43% with TT <10 nmol/L and/or cFT <230 pmol/L at presentation were reclassified as androgen sufficient at follow-up. TT was unchanged in the controls. Low testosterone levels in men presenting with an acute fracture may, at least in part, be due to an acute, fracture-associated, stress response. To avoid over diagnosis, evaluation for testosterone deficiency should be deferred until recovery from the acute event.

Commentary:Drug-Associated Atypical Femoral Fractures (DaAFFs): Balancing the Facts

The nitrogen-containing bisphosphonates (N-BPs), stable analogs of the naturally occurring pyrophosphate, are the most widely utilized drug class for osteoporosis and the first line of treatment in metastatic bone disease. They selectively bind bone mineral and are ingested by osteoclasts to impair their ability to resorb bone. Therefore, in conditions where bone resorption exceeds bone formation, N-BPs slow down the ongoing bone loss and, in doing so, reduce the risk of fracture in osteoporosis and skeletal-related events in metastatic cancer. Equally effective is denosumab, a fully human monoclonal antibody inhibiting the receptor activator of nuclear factor B ligand (RANKL), a protein essential for osteoclast development, activity, and survival. However, an unusual atraumatic or minimal-trauma fracture, the atypical femoral fracture (AFF), has been reported with increasing frequency in bisphosphonate users since the first case reports were published in 2005 and were recently reported in denosumab users. This fracture occurs between the lesser trochanter and the femoral condyles and has specific radiological features (1, 2). It also occurs in bisphosphonateor denosumabnaive individuals and in patients on weak non-bisphosphonate antiresorptive agents (3, 4). Despite its rarity, there is considerable concern among physicians and patients regarding the long-term use of bisphosphonates for fracture prevention. The first suggestions of an association of AFFs with bisphosphonates came from case reports and case series followed by observational studies that, while being hypothesis-generating, remain fraught with limitations. Because no ICD code is yet available for low-trauma AFF, certain studies have failed even to separate low-energy from high-energy fractures. The indication bias is inherent within most, if not all, such studies. Patients using antiresorptives are, by indication, at a high risk of fracture, which does not allow the attribution of AFFs to antiresorptive use as opposed to the pre-existing osteoporosis. Also, there is inconsistency of defining AFFs, and there is no radiographic adjudication for a good number of them. Furthermore, a Dutch cohort study over 11 years reported that AFFs occurred with the same frequency in non-bisphosphonate users (5). Other epidemiological studies from Europe and North America have had no access to radiographs, preventing the identification of features that are required to classify a fracture as atypical. These studies were thus performed on all subtrochanteric fractures. The outcomes, to no surprise, are at best contradictory. The rarity of AFFs prohibits the conduct of randomized safety trials that could potentially determine whether the risk of such fractures is increased in bisphosphonate or denosumab users. The only “prospective” evidence comes from the reanalysis of data from over 14 000 patients enrolled in the alendronate Fracture Intervention Trial (FIT), FIT Long-term Extension (FLEX), and the Zoledronic Acid Once Yearly (HORIZON) trials. There was no increase in subtrochanteric and femoral shaft fracture risk, or indeed the risk of any fracture, in bisphosphonatetreated patients compared with the placebo group (6). This analysis has nonetheless been rightly criticized for its lack of access to patient radiographs and the relatively short duration of bisphosphonate exposure. It was also underpowered, considering the rarity of these fractures. There is no apparent dose response between bisphosphonates and AFFs. This is highlighted in cancer patients with bone metastasis who are regularly treated with bisphosphonates or denosumab. The yearly amount of these potent antiresorptive medications prescribed could be up

Vitamin D and bone health: Epidemiologic studies.

Allelic variation in the vitamin D receptor was the first non-structural gene to be associated with osteoporosis, and together with the effects of the vitamin D system on bone homeostasis, suggested that this vitamin might have a strong role in bone health. However, controversy exists regarding what level of serum 25-hydroxyvitamin D (25(OH)D) is optimal. Current data from biochemical, observational and randomized controlled trials (RCTs), indicate serum 25(OH)D levels of at least 50 nmol l(-1) are required for normalization of parathyroid hormone (PTH) levels, to minimize the risk of osteomalacia and for optimal bone cell function. The skeletal consequences of 25(OH)D insufficiency include secondary hyperparathyroidism, increased bone turnover and bone loss and an increased risk of minimal trauma fractures. In large scale epidemiological studies, serum 25(OH)D levels are associated with bone mineral density in both men and women. However, there is mixed evidence on the effectiveness of optimizing serum 25(OH)D levels for the prevention of bone loss and minimal trauma fractures in postmenopausal women and older men. There may be some benefit on primary fracture prevention for those who have inadequate serum levels of 25(OH)D, particularly in institutionalised elderly patients, but only when combined with calcium supplements. For optimal bone health, evidence from RCTs suggests vitamin D may be considered a threshold nutrient with few further bone benefits observed at levels of 25(OH)D above which PTH is normalized. An adequate calcium intake is also imperative to gain optimum benefit from an improved vitamin D status in those with insufficient 25(OH)D levels, with an increased calcium intake being associated with suppression of PTH levels.

Bisphosphonate‐Associated Atypical Femur Fracture

ABSTRACTBackgroundBisphosphonate therapies have long been reported to decrease the risk of typical low trauma fractures in the elderly population and are commonly prescribed for this indication. In recent literature, case reports of atypical sub‐trochanteric and femoral shaft fractures have been documented in patients treated with bisphosphonates.Clinical detailsHerein we report on an 81‐year‐old woman with postmenopausal osteoporosis who presented with an atypical femoral sub‐trochanteric fracture on plain film X‐ray following approximately 5 months for query left hip bursitis after having received risedronate and alendronate therapy for &gt;5 years.OutcomesThe patient was transferred to a hospital closer to home for further rehabilitation 10 days after surgery. Her bisphosphonate therapy was ceased with advice for her general practitioner (GP) to undertake annual bone mineral density testing, as well as regular calcium and vitamin D levels. It was also recommended that the patient be referred to a bone health clinic.ConclusionThe burden of atypical fractures is significant both for the healthcare system and, more importantly, patients. There are now clear radiological changes to bone scans that give rise to the possibility of bisphosphonate‐associated atypical fractures; therefore, it is recommended that patients on long‐term bisphosphonate therapy for osteoporosis be reviewed every 5 years. In addition, GPs should be informed of the need for surveillance for prodromal symptoms and the possibility of atypical and minimal trauma fractures associated with long‐term bisphosphonate use.

Bone density and fractures in autosomal dominant hyper IgE syndrome.

Autosomal Dominant Hyper IgE Recurrent Infection Syndrome (AD-HIES) is caused by mutations in STAT3 and characterized by eczema, recurrent bacterial infections, and skeletal and connective tissue abnormalities. To further understand the minimal trauma fractures of AD-HIES, we examined bone mineral density (BMD) and laboratory markers of bone turnover. Patients with AD-HIES enrolled in a prospective natural history study were examined with dual x-ray absorptiometry (DEXA) scans and laboratory studies of bone metabolism. The number of fractures was recorded as well as clinical features of AD-HIES including scoliosis and retained primary teeth. Patients on medications with skeletal effects, including bisphosphonates, were examined separately. Twenty-three AD-HIES children (6-18 years) and 33 AD-HIES adults (21-50 years) not receiving bone-active drugs were studied. Fourteen of the 23 children (61%) had histories of minimal trauma fractures, as did 26 of the 33 adults (79%). Osteopenia or osteoporosis was found in 79% of children and adults. Only radial BMD correlated with the qualitative occurrence of fractures but it did not correlate with the numbers of fractures. Markers of bone metabolism did not correlate with minimal trauma fractures or BMD. Patients on bone-active medications had improved BMD, but still sustained fractures. Minimal trauma fractures and decreased BMD are common in AD-HIES. Low radial BMD is associated with fractures, but hip and spine BMD are not. Treatment with bisphosphonates increased BMD but its role in fracture prevention remains undefined.

Improving osteoporosis management following minimal trauma fracture in a regional setting: The Coffs Fracture Card Project

To improve osteoporosis (OSP) management following minimal trauma fracture (MTF) with few additional resources. Population intervention with serial cross-sectional analysis. Regional setting involving primary care, base hospital and private hospital. Patients with MTF. A 'Fracture Card' prompting OSP management was provided to all patients post-MTF. Patients were encouraged to attend their general practitioner (GP) with this to discuss bone health issues. The 2-year intervention was supported by a public health education campaign. Number of (i) serum 25-OH vitamin D assays, (ii) dual-energy X-ray absorptiometry (DXA) scans, and (iii) new Pharmaceutical Benefits Scheme (PBS)-subsidised prescriptions for bone protective therapy (bisphosphonates, raloxifene, strontium, teriparatide, denosumab). The number of serum 25-OH vitamin D assays ordered in Coffs Harbour increased from 329 ± 15 per month (July 2009-June 2010) to 568 ± 21 (July 2010-June 2012; P < 0.001). The number of DXA scans performed per month increased from 192 ± 14 (July 2009-June 2010) to 296 ± 12 (July 2010-June 2012; P < 0.001). There was no difference in the number of new PBS-subsidised prescriptions for bone protective therapy in the Coffs statistical subdivision over that time (176 ± 3.8 per month, July 2009-June 2010 versus 180 ± 3.5, July 2010-June 2012, P > 0.05). The intervention was associated with an increased number of 25-OH vitamin D assays and DXA scans but not with more prescriptions for bone protective therapy. This suggests that a public health education campaign and provision of a 'prompt' for GPs was only partially successful at improving OSP management post-MTF. This has driven establishment of a Fracture Liaison Service.

A fracture prevention service reduces further fractures two years after incident minimal trauma fracture

To evaluate the impact of a fracture prevention clinic service on initiation of treatment, continuing treatment and subsequent minimal trauma fractures (MTF). Participants were people aged 50 and over, with a minimal trauma fracture presenting to the Emergency Department (ED) in a large tertiary referral hospital in New South Wales, Australia, between February 2007 and March 2009. A cohort of patients who attended a Fracture Prevention Clinic (clinic group) were compared with a cohort who did not attend the clinic (non-clinic group). A telephone questionnaire was conducted with participants or their carers between December 2010 and April 2011 at least 12 months post-fracture presentation. Questionnaire items included demographics, fracture types, osteoporosis treatment, recurrent fractures and smoking and dietary habits. Data were compared using chi-squared test for categorical variables and Student's t-test or Mann-Whitney U-test for continuous variables. Two hundred and fourteen clinic attendees and 220 non-clinic attendees were surveyed between 12 and 40 months (mean 24 months) post-initial fracture. New fracture rates were lower in the clinic group (5.1%) than the non-clinic group (16.4%, P < 0.001). Treatment rates for bone fragility were higher in the clinic group (81.3%) than in the non-clinic group (54.1%, P < 0.001) with 66.8% of the clinic group and 34.1% of the non-clinic group on a bisphosphonate or strontium ranelate at the time of the survey (P < 0.001). Patients managed by a fracture prevention clinic service following a MTF have fewer new fractures and are more likely to be on treatment for bone fragility.

Prevalence of Undisclosed Osteoporosis in Patients with Minimal Trauma Fractures: A Prospective Cohort Study

Despite epidemiologic evidence for the presence of osteoporosis in patients with minimal trauma fractures, screening programs have not been routinely established in Australian ambulatory care clinics. Our study assessed the prevalence of osteoporosis and osteopenia in patients at a tertiary care hospital to gather local data to support policy change that favors bone mineral density screening. Our prospective observational study enrolled 115 patients, aged > 40 years, who had experienced a minimal trauma fracture. Inclusion criteria required that the patient had no history of testing for osteoporosis or metabolic bone disease/major pathology. The patients were recruited over a 6-month period. Eleven participants were excluded and 7 participants withdrew from the study, with a total of 97 patients completing the study. Participants were assessed for osteoporosis risk via bone mineral density measurement by dual-energy x-ray absorptiometry and blood screening for bone mineral levels, 25-hydroxyvitamin D, and parathyroid hormone levels. In our study patients, the prevalence of previously undiagnosed osteoporosis was 19%, undiagnosed osteopenia, 50%, and the standard bone mineral density was 32%. The most common risk factors for osteoporosis/osteopenia were smoking (22%), alcohol intake (16%), and corticosteroid use (9%). In 67% of patients, 25-hydroxyvitamin D level was in the low clinical range in 51% of patients, magnesium levels were in the high range and 18% of patients had elevated serum parathyroid levels. At month 12 of our study, 80 participants were available for follow-up: 2 patients had sustained a second fracture (1 was minimal trauma); 6 patients had required further surgery (3 fracture fixations, 3 for removal of internal fixation devices); 26 patients continued treatment regimens with calcium and 25-hydroxyvitamin D supplementation; and 28 patients had been prescribed bisphosphonates, with 22 patients complying with the prescription. The high prevalence of previously undiagnosed low bone mass in our study patient population, each of whom had experienced minimal trauma falls, provides impetus for the provision of osteoporosis screening programs and corresponding treatment as needed.

Burden of bisphosphonate‐associated femoral fractures

Bisphosphonates decrease the risk of typical low trauma fractures, and are commonly prescribed for this indication. The link between atypical fractures and bisphosphonate use is well established; however, who is susceptible to atypical fracture remains unclear. A number of large population-based studies have disregarded the atypical fracture risk as they have found the absolute risk to be low. This is a retrospective review of the radiographs and charts of all patients who presented with subtrochanteric and diaphyseal femoral fractures over a 5-year period. Patients were interviewed to determine functionality post-fracture. Atypical fractures represented 30.3% of all diaphyseal and subtrochanteric femoral fractures. Ninety per cent of all atypical fractures were associated with bisphosphonate use. Atypical fracture patients were younger, more active and are independent prior to fracture and experienced significant complications and self-reported level of function and health declines post-fracture. The burden of bisphosphonate-associated atypical fractures is significant. The aetiology of these fractures is unclear, and to date, no studies have demonstrated the significance of the injury for the patient. Prescription of bisphosphonate therapy for osteoporosis should be accompanied by ongoing surveillance and warning of the possibility of atypical and minimal trauma fractures.

Reasons for referral to bone densitometry in men and women aged 20–49 years: population-based data

Osteoporosis poses a significant public health problem for ageing Australians. However, approximately 25% of Australian adults aged 20-49years have osteopenia, a precursor condition to osteoporosis. Despite this, little is known about bone density testing in this age group. Reasons for referral to dual energy X-ray absorptiometry (DXA) were examined in 2,264 patients aged 20-49years, referred in 2001-2010 to the Geelong Bone Densitometry Service, Geelong Hospital, Victoria. Referral reasons were determined from clinical indication codes derived from patient records. Age, sex and bone mineral density (BMD) T scores were ascertained for each patient. The most common reason for referral for women reflected glucocorticoid use, and for men reflected fracture. Compared to women, men were more likely to have been referred because of minimal trauma fracture or low BMD (41.7 versus 27.1%, p < 0.001). No further differences were identified between the sexes, with similar numbers of referral observed for secondary osteoporosis, and monitoring of drug therapy. At the spine, and for all indications, men had a significantly greater BMD deficit compared to women (all p ≤ 0.002). After age adjustment, men who were tested due to fracture or glucocorticoid reasons had significantly greater BMD at the total hip (p ≤ 0.03). No further associations were seen after age adjustment between referral reason and BMD. Our study presents the first data examining reasons for referral to DXA among Australians aged 20-49years. Understanding health service utilisation regarding bone health in young adults is fundamental to understanding future risk, informing effective public health messages and raising awareness of osteoporosis.

A cohort study of osteoporosis health knowledge and medication use in older adults with minimal trauma fracture

We measured osteoporosis knowledge in an older adult population with minimal trauma fracture. At follow-up, health literacy and osteoporosis knowledge had not changed significantly from baseline, and 14 (23 %) patients reported not taking any osteoporosis medication. Current osteoporosis care does not result in increased patient knowledge about their disease. We aimed to measure health literacy and osteoporosis knowledge in an older adult population with minimal trauma fracture (MTF). A cohort study with 3-month follow-up in Australia was conducted. Participants were hospital admissions with an MTF confirmed by X-ray. Main outcomes were the Rapid Estimate of Adult Literacy in Medicine (REALM) and Osteoporosis Knowledge Assessment Tool (OKAT) scores. Supplementary data about osteoporosis knowledge, medication use and family practitioner visits regarding osteoporosis were obtained. Complete data are available in 60 participants. On admission, 97 % participants had high REALM scores [mean (range) 64.7 (46.66)] and low OKAT scores [8.83 (2.16)]. At follow-up, three (5 %) participants had a further fracture. REALM and OKAT scores had not changed significantly from baseline. There was no association between OKAT score at follow-up and current treatment for osteoporosis, beliefs relating to treatment or bone health, and discussion with health care worker since discharge after adjusting for Mini Mental State Examination score. Health literacy or reading ability was not related to OKAT score. Osteoporosis knowledge assessed by the OKAT did not improve in the 3months after MTF in this cohort of literate older adults, although there was some evidence of improvements in health beliefs. Current care in osteoporosis does not increase patient knowledge about their disease adequately which may impair patient effectiveness in obtaining appropriate treatment.

Sustainability of a pharmacist-driven pathway for osteoporosis-related fractures on an orthopaedic unit after a 5-year period

Diagnosis and management of osteoporosis in hospitals are poor. Effective medications for reducing fracture risk are often underutilised in hospital settings. Studies have shown that improvements in secondary prevention of osteoporosis can occur with the implementation of clinical pathways and are effective in improving the prescription for osteoporosis medications. We aimed to assess the long-term sustainability of the benefit of the osteoporosis pathway implemented at The Queen Elizabeth Hospital, Adelaide, Australia, in 2003. An audit was performed to review the rate of prescription for osteoporosis therapy 5 years after the implementation of a pharmacist-driven osteoporosis pathway in patients presented with a minimal trauma fracture and admitted to the Department of Orthopaedics at The Queen Elizabeth Hospital. Our review of a 5-year period shows that the rate of prescription for osteoporosis therapy in this patient group is 95%. The pharmacist-driven osteoporosis pathway at The Queen Elizabeth Hospital has sustained the rate of prescription for osteoporosis therapy over a prolonged period of time.

Antipsychotic-Induced Hyperprolactinaemia

Antipsychotic medications are a potential cause of hyperprolactinaemia and may be implicated in the development of pituitary adenomas. This review examines the effect of different antipsychotic medications on prolactin and sexual function, and provides practical guidelines for investigation and management of antipsychotic-induced hyperprolactinaemia. Literature review. Antipsychotic-induced hyperprolactinaemia occurs overall in up to 70% of patients with schizophrenia, depending on the medications used. It is associated with significant levels of hypogonadism and sexual dysfunction, which in general relates to the degree of prolactin elevation. A consequence of the hypogonadism is clinically significant bone loss which may lead to osteoporosis and increased risk of minimal trauma fracture. Where the potentially offending drug cannot be safely withdrawn to document a normal prolactin, imaging with MRI should be undertaken to exclude a structural pituitary lesion. The management strategy of choice is switching to a prolactin-sparing antipsychotic. Sex steroid replacement can reverse many of the adverse effects including the hypogonadal symptoms and bone loss. Low dose dopamine agonist therapy should be used with caution as a third line treatment, since there have been cases of dopamine agonist-induced exacerbation of psychosis. There is a need for a randomised controlled trial of low dose dopamine agonist therapy versus sex steroid replacement to establish the relative safety and efficacy of each approach.